

## Report 4: Severity of 2019-novel coronavirus (nCoV)

Ilaria Dorigatti<sup>†</sup>, Lucy Okell<sup>†</sup>, Anne Cori, Natsuko Imai, Marc Baguelin, Sangeeta Bhatia, Adhiratha Boonyasiri, Zulma Cucunubá, Gina Cuomo-Dannenburg, Rich FitzJohn, Han Fu, Katy Gaythorpe, Arran Hamlet, Wes Hinsley, Nan Hong, Min Kwun, Daniel Laydon, Gemma Nedjati-Gilani, Steven Riley, Sabine van Elsland, Erik Volz, Haowei Wang, Raymond Wang, Caroline Walters, Xiaoyue Xi, Christl Donnelly, Azra Ghani, Neil Ferguson\*. With support from other volunteers from the MRC Centre.<sup>1</sup>

WHO Collaborating Centre for Infectious Disease Modelling  
MRC Centre for Global Infectious Disease Analysis  
Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA)  
Imperial College London

\*Correspondence: [neil.ferguson@imperial.ac.uk](mailto:neil.ferguson@imperial.ac.uk)<sup>1</sup>See full list at end of document. <sup>†</sup>These two authors contributed equally.

### Summary

We present case fatality ratio (CFR) estimates for three strata of 2019-nCoV infections. For cases detected in Hubei, we estimate the CFR to be 18% (95% credible interval: 11%-81%). For cases detected in travellers outside mainland China, we obtain central estimates of the CFR in the range 1.2-5.6% depending on the statistical methods, with substantial uncertainty around these central values. Using estimates of underlying infection prevalence in Wuhan at the end of January derived from testing of passengers on repatriation flights to Japan and Germany, we adjusted the estimates of CFR from either the early epidemic in Hubei Province, or from cases reported outside mainland China, to obtain estimates of the overall CFR in all infections (asymptomatic or symptomatic) of approximately 1% (95% confidence interval 0.5%-4%). It is important to note that the differences in these estimates does not reflect underlying differences in disease severity between countries. CFRs seen in individual countries will vary depending on the sensitivity of different surveillance systems to detect cases of differing levels of severity and the clinical care offered to severely ill cases. All CFR estimates should be viewed cautiously at the current time as the sensitivity of surveillance of both deaths and cases in mainland China is unclear. Furthermore, all estimates rely on limited data on the typical time intervals from symptom onset to death or recovery which influences the CFR estimates.

### SUGGESTED CITATION

Ilaria Dorigatti, Lucy Okell, Anne Cori *et al.* Severity of 2019-novel coronavirus (nCoV). Imperial College London (10-02-2020), doi: <https://doi.org/10.25561/77154>.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


## 1. Introduction: Challenges in assessing the spectrum of severity

There are two main challenges in assessing the severity of clinical outcomes during an epidemic of a newly emerging infection:

1. Surveillance is typically biased towards detecting clinically severe cases, particularly at the start of an epidemic when diagnostic capacity is limited (Figure 1). Estimates of the proportion of fatal cases (*the case fatality ratio*, CFR) may thus be biased upwards until the extent of clinically milder disease is determined [1].
2. There can be a period of two to three weeks between a case developing symptoms, subsequently being detected and reported and observing the final clinical outcome. During a growing epidemic the final clinical outcome of the majority of the reported cases is typically unknown. Dividing the cumulative reported deaths by reported cases will underestimate the CFR among these cases early in an epidemic [1-3].

Figure 1 illustrates the first challenge. Published data from China suggest that the majority of detected and reported cases have moderate or severe illness, with atypical pneumonia and/or acute respiratory distress being used to define suspected cases eligible for testing. In these individuals, clinical outcomes are likely to be more severe, and hence any estimates of the CFR are likely to be high.

Outside mainland China, countries alert to the risk of infection being imported via international travel have instituted surveillance for 2019-nCoV infection with a broader set of clinical criteria for defining a suspected case, typically including a combination of symptoms (e.g. cough + fever) combined with recent travel history to the affected region (Wuhan and/or Hubei Province). Such surveillance is therefore likely to pick up clinically milder cases as well as the more severe cases also being detected in mainland China. However, by restricting testing to those with a travel history or link, it is also likely to miss other symptomatic cases (and possibly hospitalised cases with atypical pneumonia) that have occurred through local transmission or through travel to other affected areas of China.



**Figure 1: Spectrum of cases for 2019-nCoV, illustrating imputed sensitivity of surveillance in mainland China and in travellers arriving in other countries or territories from mainland China.**

Finally, the bottom of the pyramid represents the likely largest population of those infected with either mild, non-specific symptoms or who are asymptomatic. Quantifying the extent of infection overall in the population requires random population surveys of infection prevalence. The only such data at present for 2019-nCoV are the PCR infection prevalence surveys conducted in exposed expatriates who have recently been repatriated to Japan, Germany and the USA from Wuhan city (see below).

To obtain estimates of the severity of 2019-nCoV across the full severity range we examined aggregate data from Hubei Province, China (representing the top two levels – deaths and hospitalised cases – in Figure 1) and individual-level data from reports of cases outside mainland China (the top three levels and perhaps part of the fourth level in Figure 1). We also analysed data on infections in repatriated expatriates returning from Hubei Province (representing all levels in Figure 1).

## **2. Current estimates of the case fatality ratio**

The CFR is defined as the proportion of cases of a disease who will ultimately die from the disease. For a given case definition, once all deaths and cases have been ascertained (for example at the end of an epidemic), this is simply calculated as deaths/cases. However, at the start of the epidemic this ratio underestimates the true CFR due to the time-lag between onset of symptoms and death [1-3]. We adopted several approaches to account for this time-lag and to adjust for the unknown final clinical outcome of the majority of cases reported both inside and outside China (cases reported in mainland China and those reported outside mainland China) (see Methods section below). We present the range of resulting CFR estimates in Table 1 for two parts of the case severity pyramid. Note that all estimates have high uncertainty and therefore point estimates represent a snapshot at the current time and may change as additional information becomes available. Furthermore, all data sources have inherent potential biases due to the limits in testing capacity as outlined earlier.

**Table 1: Estimates of CFR for two severity ranges: cases reported in mainland China, and those reported outside. All estimates quoted to two significant figures.**

Severity range	Method and data used	Time to outcome distributions used	CFR
<b><u>China: Epidemic currently in Hubei</u></b>	Parametric model fitted to publicly reported number of cases and deaths in Hubei as of 5 <sup>th</sup> February, assuming exponential growth at rate 0.14/day.	Onset-to-death estimated from 26 deaths in China; assume 5-day period from onset to report and 1-day period from death to report.	18% <sup>1</sup> (95% credible interval: 11-81%)
<b><u>Outside mainland China: cases in travellers from mainland China to other countries or territories (showing a broader spectrum of symptoms than cases in Hubei, including milder disease)</u></b>	Parametric model fitted to reported traveller cases up to 8 <sup>th</sup> February using both death and recovery outcomes and inferring latest possible dates of onset in traveller cases <sup>2</sup> .	Onset-to-death estimated from 26 deaths in China; onset-to-recovery estimated from 36 cases detected outside mainland China <sup>4</sup> .	5.1% <sup>3</sup> (95% credible interval: 1.1%-38%)
	Parametric model fitted to reported traveller cases up to 8 <sup>th</sup> February using only death outcome and inferring latest possible unreported dates of onset in traveller cases <sup>2</sup> .	Onset-to-death estimated from 26 deaths in China.	5.6% <sup>1</sup> (95% credible interval: 2.0%-85%)
	Kaplan-Meier-like non-parametric model (CASEFAT Stata module [4]) fitted to reported traveller cases up to 8 <sup>th</sup> February using both death and recovery outcomes <sup>2</sup> .	Hazards of death and recovery estimated as part of method.	1.2% <sup>3,4</sup> (95% confidence interval: 0.9%-26%)
<b><u>All infections</u></b>	Scaling CFR estimate for Hubei for the level of infection under-ascertainment estimated from infection prevalence detected in repatriation flights, assuming infected individuals test positive for 14 days	As first row	0.9% (95% confidence interval: 0.5%-4.0%)
	As previous row, but assuming infected individuals test positive for 7 days	As first row	0.8% (95% confidence interval: 0.4%-3.0%)


<sup>1</sup>Mode quoted for Bayesian estimates, given uncertainty in the tail of the onset-to-death distribution. <sup>2</sup>Estimates made without imputing onset dates in traveller cases for whom onset dates are unknown are slightly higher than when onset dates are imputed. <sup>3</sup>Maximum likelihood estimate. <sup>4</sup>This estimate relies on information from just 2 deaths reported outside mainland China thus far and therefore has wide uncertainty. Both of these deaths occurred a relatively short time after onset compared with the typical pattern in China.

Use of data on those who have recovered among exported cases gives very similar point estimates to just relying on death data, but a rather narrower uncertainty range. This highlights the value of case follow-up data on both fatal and non-fatal cases.

Given that the estimates of CFR across all infections rely on a single point estimate of infection prevalence, they should be treated cautiously. In particular, the sensitivity of the diagnostics used to test repatriated passengers is not known, and it is unclear when infected people might test positive, or how representative those passengers were of the general population of Wuhan (their infection risk might have been higher or lower than the general population). Additional representative studies to assess the extent of mildly symptomatic or asymptomatic infection are therefore urgently needed.

Figure 2 shows projected expected numbers of deaths detected in cases detected up to 4<sup>th</sup> February outside mainland China over the next few weeks for different values of the CFR. If no further deaths are reported amongst this group (and indeed if many of those now in hospital recover and are

discharged) in the next 5 to 10 days, then we expect the upper bound on estimates of the CFR in this population to reduce. We note that the coming one to two weeks should allow CFR estimates to be refined.



**Figure 2: Projected numbers of deaths in cases detected outside China up to 8<sup>th</sup> February for different values of the CFR in that population.**

### 3. Methods

#### A) Intervals between onset of symptoms and outcome

During a growing epidemic, the reported cases are generally identified some time before knowing the clinical outcome of each case. For example, during the 2003 SARS epidemic, the average time between onset of symptoms and either death or discharge from hospital was approximately three weeks. To interpret the relationship between reported cases and deaths, we therefore need to account for this interval. Two factors need to be considered; a) that we have not observed the full distribution of outcomes of the reported cases (i.e. censoring) and b) that our sample of cases is from a growing epidemic and hence more reported cases have been infected recently compared to one to two weeks ago. The latter effect is frequently ignored in analyses but leads to a downwards biased central estimate of the CFR.

If  $f_{OD}(\cdot)$  denotes the probability density function (PDF) of time from symptom onset to death, then the PDF that we observe a death at time  $t_d$  with assumed onset  $\tau$  days ago is

$$g_{OD}(\tau | t_d) = \frac{f_{OD}(\tau) o(t_d - \tau)}{\int_0^{\infty} f_{OD}(\tau') o(t_d - \tau') d\tau'}$$

where  $o(t)$  denotes the observed number of onsets that occurred at time  $t$ . For an exponentially growing epidemic, we assume that  $o(t) = o_0 e^{rt}$  where  $o_0$  is the initial number of onsets (at  $t=0$ ) and  $r$  is the epidemic growth rate. Substituting this, we get

$$g_{OD}(\tau | t_d) = \frac{f_{OD}(\tau) e^{r\tau}}{\int_0^{\infty} f_{OD}(\tau') e^{r\tau'} d\tau'}$$

We can therefore fit the distribution  $g_{OD}(\cdot)$  to the observed data and correct for the epidemic growth rate to estimate parameters for  $f_{OD}(\cdot)$ , the true distribution for a given estimate of  $r$ .

If we additionally assume that onsets were poorly observed prior to time  $T_{min}$  then we can include censoring:

$$g_{OD}(\tau | t_d) = \frac{f_{OD}(\tau) e^{r\tau}}{\int_0^{t_d - T_{min}} f_{OD}(\tau') e^{r\tau'} d\tau'}$$

For the special case that we model  $f_{OD}(\tau)$  as a gamma distribution parameterised in terms of its mean  $m$  and the ratio of the standard deviation to the mean,  $s$ , namely  $f_{OD}(\tau | m, s)$ , it can be shown that

$$g_{OD}(\tau | t_d, m', s') = \frac{f_{OD}(\tau | m / (1 + rms^2), s)}{\int_0^{t_d - T_{min}} f_{OD}(\tau' | m / (1 + rms^2), s) d\tau'}$$

where the transformed mean and standard deviation-to-mean ratios are  $m' = \frac{m}{(1 + rms^2)}$ ,  $s' = s$ .

Therefore, the Bayesian posterior distribution for  $m$  and  $s$  (up to a constant factor equal to the total probability) is proportional to the likelihood (over all intervals):

$$P(m, s | \{\tau, t_d\}) \propto \prod_i g_{OD}(\tau_i | t_{d,i}, m, s) P(m, s),$$

where the product is over a dataset of observed intervals and times of death  $\{\tau, t_d\}$  and  $P(m, s)$  is the prior distribution for  $m$  and  $s$ . This is constant for a uniform prior distribution or can be derived, for instance, by fitting this model to the complete dataset of observed onset-to-death intervals from previous epidemics (e.g. in this case the 2003 SARS epidemic in Hong Kong). Note that for a fully

observed epidemic, it is not necessary to account for epidemic growth provided there was no change in clinical management (and thus the interval distribution) over time.

We can infer other interval distributions such as the onset-to-recovery distribution,  $f_{OR}(\cdot)$  (but also the serial interval distribution and incubation period distribution) in a similar manner, given relevant data on the timing of events. It should be noted that inferring all such interval distributions needs to take account of epidemic growth.

For the analyses presented here, we fitted  $f_{OD}(\cdot)$  to data from 26 deaths from 2019-nCoV reported in mainland China early in the epidemic and we fitted  $f_{OR}(\cdot)$  to 29 cases detected outside mainland China. Uninformative uniform prior distributions were used for both.

The estimates of key parameters are shown in Table 2.

**Table 2: Estimates of parameters for onset-to-death and onset-to-recovery distributions**

Distribution	Data Source	mean (mode, 95% credible interval)	SD/mean (mode, 95% credible interval)
Onset-to-recovery	29 2019-CoV cases detected outside mainland China	22.2 days (18-83)	0.45 (0.35-0.62)
Onset-to-death	26 2019-nCoV deaths from mainland China	22.3 days (18-82)	0.42 (0.33-0.6)

## B) Estimates of the Case Fatality Ratio from individual case data

### Parametric models

We can infer the CFR from individual data on dates of symptom onset, death and recovery. Continuing our notation from above, let  $f_{OD}(\cdot)$  denote the distribution of times from symptom onset to death,  $f_{OR}(\cdot)$  denote the distribution of times from onset to recovery, and  $c$  denote the CFR.

The probability that a patient dies on day  $t_d$  given onset at time  $t_o$ , conditional on survival to that time is given by:

$$p_d(t_d - t_o | c, m_{OD}, s_{OD}) = c \int_{t_d - t_o}^{t_d - t_o + 1} f_{OD}(\tau) d\tau.$$

Similarly, the probability that a patient recovers on day  $t_r$ , given onset at time  $t_o$ , is given by:

$$p_r(t_r - t_o | c, m_{OR}, s_{OR}) = (1 - c) \int_{t_r - t_o}^{t_r - t_o + 1} f_{OR}(\tau) d\tau.$$

Here  $m_{OD}, s_{OD}$  are the mean and standard deviation-to-mean ratio for the onset-to-death distribution, and  $m_{OR}, s_{OR}$  are those for the onset-to-recovery distribution.

Finally, the probability that a patient remains in hospital at the last date for which data are available,  $T$ , is

$$p_h(T - t_o | c, m_{OD}, s_{OD}, m_{OR}, s_{OR}) = (1 - c) \int_{T - t_o}^{\infty} f_{OR}(\tau) d\tau + c \int_{T - t_o}^{\infty} f_{OD}(\tau) d\tau.$$

The overall likelihood of all observed deaths, recoveries and cases remaining in hospital is

$$P(\mathbf{t}_d, \mathbf{t}_r, T | c, m_{OD}, s_{OD}, m_{OR}, s_{OR}, \mathbf{t}_o) = \prod_{i \in \{\text{dead by } T\}} P_d(t_{d,i} | t_{o,i}, c, m_{OD}, s_{OD}) \prod_{i \in \{\text{recovered by } T\}} P_r(t_{r,i} | t_{o,i}, c, m_{OR}, s_{OR}) \prod_{i \in \{\text{hospitalised at } T\}} P_h(T_i | t_{o,i}, c, m_{OD}, s_{OD}, m_{OR}, s_{OR})$$

It is also possible to infer  $c$  from data just on deaths and ‘non-deaths’, grouping the currently hospitalised and recoveries together:

$$P(\mathbf{t}_d, \mathbf{t}_r, T | c, m_{OD}, s_{OD}, \mathbf{t}_o) = \prod_{i \in \{\text{dead by } T\}} P_d(t_{d,i} | t_{o,i}, c, m_{OD}, s_{OD}) \prod_{i \in \{\text{not dead at } T\}} P_h(T | t_{o,i}, c, m_{OD}, s_{OD}, m_{OR}, s_{OR})$$

In a Bayesian context, the posterior distribution is given by

$$P(c | \mathbf{t}_d, \mathbf{t}_r, \mathbf{t}_o, T) \propto \int P(\mathbf{t}_d, \mathbf{t}_r, T | c, m_{OD}, s_{OD}, m_{OR}, s_{OR}, \mathbf{t}_o) P(m_{OR}, s_{OR} | \{\tau, \mathbf{t}_d\}_{\text{old}}) P(m_{OD}, s_{OD} | \{\tau, \mathbf{t}_d\}_{\text{old}}) P(c) dm_{OD} ds_{OD} dm_{OR} ds_{OR}$$

where  $P(m_{OD}, s_{OD} | \{\tau, \mathbf{t}_d\}_{\text{old}})$  is the prior distribution for the onset-to-death distribution obtained by fitting to previous epidemics (e.g. in this case the 2003 SARS epidemic in Hong Kong)  $\{\tau, \mathbf{t}_d\}_{\text{old}}$ , and  $P(m_{OR}, s_{OR} | \{\tau, \mathbf{t}_r\}_{\text{old}})$  is the comparable prior distribution for time from onset to recovery.

We assumed gamma-distributed onset-to-death and onset-to-recovery distributions (see above).

We fitted this model to the observed onset, recovery and death times in 290 international travellers from mainland China reported up to 8<sup>th</sup> February. For approximately 50% of these travellers, the date of onset was not reported. To allow us to fit the model to all cases, for those travellers we imputed an estimate of the onset date as the first known contact with healthcare services – taken as the earliest of the date of hospitalisation, date of report or date of confirmation. We note this is the latest possible onset date and may therefore increase our estimates of CFR.

We also fitted a variant of this model where recoveries were ignored, given that they may be systematically under-ascertained and hence introduce a bias in the estimate.

Posterior distributions were calculated numerically on a hypercube grid of the parameters to be inferred ( $c, m_{OD}, s_{OD}, m_{OR}, s_{OR}$ ). Marginal distributions were computed for  $c$ .

**Kaplan-Meier-like non-parametric model**

We used a non-parametric Kaplan-Meier-like method originally developed and applied to the 2003 SARS epidemic in Hong Kong [2]. The analysis was implemented using the CASEFAT Stata Module [4].

**C) Estimates of the Case Fatality Ratio from aggregated case data**

With posterior estimates of  $f_{OD}(\cdot)$  derived from case data collected in the early epidemic in Wuhan, it is possible to estimate the CFR from daily reports of confirmed cases and deaths in China, under the assumption that the daily new incidence figures reported represent recent deaths and cases.

Let the incidence of deaths and onsets (newly symptomatic cases at time  $t$  be  $D(t)$  and  $C(t)$ , respectively. Given knowledge of the onset-to-death distribution,  $f_{OD}(\cdot)$ , the expected number of deaths at time  $t$  is given by

$$D(t) = c \int_0^{\infty} C(t-\tau) f_{OD}(\tau) d\tau$$

Assuming cases are growing exponentially as  $C(t) = C_0 \exp(rt)$ , we have

$$D(t) = cC(t) \int_0^{\infty} f_{OD}(\tau) e^{-r\tau} d\tau = czC(t)$$

where

$$z = \int_0^{\infty} f_{OD}(\tau) e^{-r\tau} d\tau$$

Assuming a gamma distribution form for  $f_{OD}(\cdot)$ , and parameterising as above in terms of the mean and the standard deviation-to-mean ratio,  $m$  and  $s$ , respectively, one can show that  $z$  is:

$$z(r, m, s) = \frac{1}{(1 + rms^2)^{1/s^2}}$$

Thus we assumed the probability of observing  $D(t)$  deaths given  $C(t)$  at time  $t$  is a binomial draw from  $C(t)$  with probability  $cz$ . The term  $z$  is a downscaling of the actual CFR,  $c$ , to reflect epidemic growth. Heuristically, if the mean onset-to-death interval is 20 days, and the doubling time of the epidemic is, say, 5 days, then deaths now correspond to onsets occurring when incidence of cases was  $2^4 = 16$  fold smaller than today, meaning the crudely estimated CFR (cumulative deaths/ cumulative cases) needs to be scaled up by the same factor.

Ignoring constant terms in the binomial probability not involving  $c$ ,  $m$  or  $s$ , the posterior distribution for  $c$  is:

$$P(c | C(t), D(t), m, s) \propto (cz(r, m, s)C(t))^{D(t)} \exp(-cz(r, m, s)C(t)) P(m, s) P(c)$$

where  $P(c)$  is the prior distribution on  $c$  (assumed uniform) and  $P(m, s)$  is the prior distribution on the onset-to-death distribution,  $f_{OD}(\cdot)$ , which we took to be the posterior distribution obtained

by fitting to observed onset-to-death distribution for 26 cases in the early epidemic in Wuhan, itself fitted with a prior distribution based on SARS data (see above).

The official case reports do not give dates of symptom onset or death, so we assumed that deaths were reported 4 days more promptly than onsets, given the delays in healthcare seeking and testing involved in confirming new cases, versus the follow-up and recording of deaths of the cases already in the database. Assuming this difference in reporting delays is longer than 4 days results in lower estimates of the CFR, while assuming the difference is shorter than 4 days gives higher estimates. Thus, we compared 45 new deaths reported on 1<sup>st</sup> February with 3156 new cases reported on 5<sup>th</sup> February.

In addition, while both cases and deaths were growing approximately exponentially in the 10 days prior to 5<sup>th</sup> February, the numbers of cases have been growing faster than deaths. We assumed this reflects improved surveillance of milder cases over time, and thus used an estimate of the growth rate in deaths of  $r = 0.14 / \text{day}$ , corresponding to a 5-day doubling time. Assuming a higher value of  $r$  gives a higher estimate of the CFR.

Resulting estimates of the CFR showed little variation if calculated for each of the 7 days prior to 5<sup>th</sup> February.

#### D) Translating prevalence to incidence and estimating a CFR for all infections

Translating the severity estimates in

Table 1 into estimates of CFR for all cases of infection with 2019-nCoV requires knowledge of the proportion of all infections being detected in either China or overseas. To do so we use a single point estimate of prevalence of infection from the testing of all passengers returning on four repatriation flights to Japan and Germany in the period 29<sup>th</sup> January – 1<sup>st</sup> February. Infection was detected in passengers from each flight. In total 10 infections were confirmed in approximately 750 passengers (passenger numbers are known for 3 flights and were estimated to be ~200 for the fourth). This gives an estimate of detectable infection prevalence of 1.3% (exact 95% binomial confidence interval: 0.7%-2.4%).

Let us assume infected individuals test positive by PCR to 2019-nCoV infection from  $l$  days before onset of clinical symptoms to  $n-l$  days after. Then the infection prevalence at time  $t$ ,  $y(t)$  is related to the incidence of new cases,  $C(t)$  by:

$$y(t) = \int_{-l}^{n-l} C(t-\tau) d\tau / N$$

Here  $N$  is the population of the area sampled (here assumed to be Wuhan). Assuming incidence is growing as  $C(t) = C_0 \exp(rt)$ , with  $r=0.14/\text{day}$  (5-day doubling time), this gives

$$y(t) = C(t+l)[1 - \exp(-rn)] / N$$

Here we assume  $l=1$  day and examine  $n=7$  and 14 days.

Thus we estimated a daily incidence estimate of 220 (95% confidence interval: 120-400) case onsets per day per 100,000 of population in Wuhan on 31<sup>st</sup> January assuming infections are detectable for 14 days, and 300 (95% confidence interval: 160-550) case onsets per day per 100,000 assuming infections are detectable for 7 days. Taking the 11 million population of Wuhan city, this implied a total of 24,000 (95% confidence interval: 13,000-44,000) case onsets in the city on that date assuming infections are detectable for 14 days, and 33,000 (95% confidence interval: 18,000-60,000) assuming infections are detectable for 7 days. It should be noted that a number of the detected infections on the repatriation flights were asymptomatic (at least at the time of testing), therefore these total estimates of incidence might include a proportion of very mildly symptomatic or asymptomatic cases.

Assuming an average 4 days<sup>1</sup> between the onset of symptoms and case report in Wuhan City, the above estimates can be compared with the 1242 reported confirmed cases on 3<sup>rd</sup> February in Wuhan City [5]. This implies 19-fold (95% confidence interval: 11-35) under-ascertainment of infections in Wuhan assuming infections are detectable for 14 days (including from 1 day prior to symptoms), and 26-fold (95% confidence interval: 15-48) assuming infections are detectable for 7 days (including 1 day prior to symptoms).

Under the assumption that all 2019-nCoV deaths are being reported in Wuhan city, we can then divide our estimates of CFR in China by these under-ascertainment factors. Taking our 18% CFR among cases in Hubei (first row of Table 1), this implies a CFR among all infections of 0.9% (95% confidence interval: 0.5%-4.3%) assuming infections are detectable via PCR for 14 days, and 0.8% (95% confidence interval: 0.4%-3.1%) assuming infections are detectable for 7 days.

---

<sup>1</sup> This value is plausible from publicly available case reports. Longer durations between onset of symptoms and report will lead to higher estimates of the degree of under-ascertainment.

Similar estimates are obtained if one uses estimates of CFR in exported cases as the comparator: we estimate that surveillance outside mainland China is approximately 4 to 5-fold more sensitive at detecting cases than that in China.

#### E) Forward Projections of Expected Deaths in Travellers

Using our previous notation, let  $o_{travellers}(t)$  denote the onsets in travellers from mainland China at time  $t \leq T_{max}$  where  $T_{max}$  is the most recent time (8<sup>th</sup> February in this analysis). Using our central estimate of the onset-to-death interval obtained from the 26 deaths in mainland China,  $f_{OD}(m, s, t)$ , we obtain an estimate of the expected number of deaths occurring at time  $t$ ,  $D(t)$  from:

$$D(t) = c \int_0^{\infty} o_{travellers}(t - \tau) f_{OD}(\tau) d\tau$$

where  $c$  is the CFR.

## 4. Data Sources

### A) Data on early deaths from mainland China

Data on the characteristics of 39 cases who died from 2019-nCoV infection in Hubei Province were collated from several websites. Of these, the date of onset of symptoms was not available for 5 cases. We restricted our analysis to those who died up to 21<sup>st</sup> January leaving 26 deaths for analysis. These data are available from website as [hubei\\_early\\_deaths\\_2020\\_07\\_02.csv](#)

### B) Data on cases in international travellers

We collated data on 290 cases in international travellers from websites and media reports up to 8<sup>th</sup> February. These data are available from website as [international\\_cases\\_2020\\_08\\_02.csv](#)

### C) Data on infection in repatriated international Wuhan residents

Data on infection prevalence in repatriated expatriates returning to their home countries were obtained from media reports. These data are summarised in Table 3. Further data from a flight returning to Malaysia reported two positive cases on 5<sup>th</sup> February – giving a prevalence at this time point of 2% which remains consistent with our estimate.

**Table 3: Data on confirmed infections in passengers on repatriation flights from Wuhan.**

	Country of Destination	Number of Passengers	Number Confirmed	Number Confirmed who were Symptomatic	Number Confirmed who were Asymptomatic
1	Japan	206	4	2	2
2	Japan	210	2	0	2
3	Japan	Not reported – assume 200	2	1	1
4	Germany	124	2	-	-
5*	Malaysia	207	2	0	2

\*Not used in our analysis but noted here for completeness.

## **5. Acknowledgements**

We are grateful to the following hackathon participants from the MRC Centre for Global Infectious Disease Analysis for their support in extracting data: Kylie Ainsile, Lorenzo Cattarino, Giovanni Charles, Georgina Charnley, Paula Christen, Victoria Cox, Zulma Cucunubá, Joshua D'Aeth, Tamsin Dewé, Amy Dighe, Lorna Dunning, Oliver Eales, Keith Fraser, Katy Gaythorpe, Lily Geidelberg, Will Green, David Jørgensen, Mara Kont, Alice Ledda, Alessandra Lochen, Tara Mangal, Ruth McCabe, Kate Mitchell, Andria Mousa, Rebecca Nash, Daniela Olivera, Saskia Ricks, Nora Schmit, Ellie Sherrard-Smith, Janetta Skarp, Isaac Stopard, Hayley Thompson, Juliette Unwin, Juan Vesga, Caroline Walters.

## 6. References

1. Garske, T., et al., *Assessing the severity of the novel influenza A/H1N1 pandemic*. BMJ, 2009. **339**: p. b2840.
2. Ghani, A.C., et al., *Methods for estimating the case fatality ratio for a novel, emerging infectious disease*. Am J Epidemiol, 2005. **162**(5): p. 479-86.
3. Lipsitch, M., et al., *Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks*. PLoS Negl Trop Dis, 2015. **9**(7): p. e0003846.
4. Griffin, J. and A. Ghani, *CASEFAT: Stata module for estimating the case fatality ratio of a new infectious disease*. Statistical Software Components, 2005. **S454601**.
5. People's Republic of China. *National Health Commission of the People's Republic of China*. 2020 [Accessed 03/02/2020]; Available from: [www.nhc.gov.cn/](http://www.nhc.gov.cn/).